PMID- 38510847
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240322
IS  - 2590-0889 (Electronic)
IS  - 2590-0889 (Linking)
VI  - 6
IP  - 2
DP  - 2024 Jun
TI  - The effect of taurolidine on the time-to-positivity of blood cultures.
PG  - 100352
LID - 10.1016/j.infpip.2024.100352 [doi]
LID - 100352
AB  - BACKGROUND: Taurolidine containing lock solutions (TL) are a promising method for 
      the prevention of central line associated bloodstream infections. Per accident, 
      the TL may not always be aspirated from the central venous catheter (CVC) before 
      blood cultures are obtained. The TL could, unintentionally, end up in a blood 
      culture vial, possibly altering the results. The aim of this study was to 
      investigate the effect of the TLs on the detection of microbial growth in blood 
      culture vials. METHODS: Different lock solutions (taurolidine-citrate-heparin 
      (TCHL), taurolidine, heparin, citrate or NaCl) were added to BD BACTEC(TM) blood 
      culture vials (Plus Aerobic/F, Lytic/10 Anaerobic/F or Peds Plus/F) before 
      spiking with Staphylococcus aureus (ATCC 29213 or a clinical strain) or 
      Escherichia coli (ATCC 25922 or a clinical strain) in the presence and absence of 
      blood. Subsequently, blood culture vials were incubated in the BD BACTEC FX 
      instrument with Time-to-positivity (TTP) as primary outcome. In addition, the 
      effect of the TCHL on a variety of other micro-organisms was tested. DISCUSSION: 
      In the presence of taurolidine, the TTP was considerably delayed or vials even 
      remained negative as compared to vials containing heparin, citrate or NaCl. This 
      effect was dose-dependent. The delayed TTP was much less pronounced in the 
      presence of blood, but still notable. CONCLUSION: This study stresses the 
      clinical importance of discarding TLs from the CVC before obtaining a blood 
      culture.
CI  - (c) 2024 The Authors.
FAU - van den Bosch, C H
AU  - van den Bosch CH
AD  - Princess Maxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, 
      Utrecht, The Netherlands.
FAU - Moree, J E P
AU  - Moree JEP
AD  - Princess Maxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, 
      Utrecht, The Netherlands.
AD  - Department of Medical Microbiology, University Medical Centre Utrecht, 
      Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
FAU - Peeters, S
AU  - Peeters S
AD  - Department of Medical Microbiology, University Medical Centre Utrecht, 
      Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
FAU - Lankheet, M
AU  - Lankheet M
AD  - Department of Medical Microbiology, University Medical Centre Utrecht, 
      Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
FAU - van der Steeg, A F W
AU  - van der Steeg AFW
AD  - Princess Maxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, 
      Utrecht, The Netherlands.
FAU - Wijnen, M H W A
AU  - Wijnen MHWA
AD  - Princess Maxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, 
      Utrecht, The Netherlands.
FAU - van de Wetering, M D
AU  - van de Wetering MD
AD  - Princess Maxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, 
      Utrecht, The Netherlands.
FAU - van der Bruggen, J T
AU  - van der Bruggen JT
AD  - Department of Medical Microbiology, University Medical Centre Utrecht, 
      Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20240229
PL  - England
TA  - Infect Prev Pract
JT  - Infection prevention in practice
JID - 101777928
PMC - PMC10950745
OTO - NOTNLM
OT  - Blood culture
OT  - Central line-associated bloodstream infection
OT  - Central venous access
OT  - Paediatric oncology
OT  - Taurolidine
OT  - Taurolock
EDAT- 2024/03/21 06:43
MHDA- 2024/03/21 06:44
PMCR- 2024/02/29
CRDT- 2024/03/21 04:17
PHST- 2023/11/03 00:00 [received]
PHST- 2024/02/07 00:00 [accepted]
PHST- 2024/03/21 06:44 [medline]
PHST- 2024/03/21 06:43 [pubmed]
PHST- 2024/03/21 04:17 [entrez]
PHST- 2024/02/29 00:00 [pmc-release]
AID - S2590-0889(24)00016-7 [pii]
AID - 100352 [pii]
AID - 10.1016/j.infpip.2024.100352 [doi]
PST - epublish
SO  - Infect Prev Pract. 2024 Feb 29;6(2):100352. doi: 10.1016/j.infpip.2024.100352. 
      eCollection 2024 Jun.